Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

This early-phase study is testing a new drug called YH32367 in patients with HER2-positive cancers (tumors that have too much of a protein called HER2 on their surface) that are locally advanced or have spread to other organs. It includes a specific focus on bile duct cancers and other HER2-positive solid tumors. **You may be eligible if...** - Your tumor has been confirmed to be HER2-positive by pathology testing - For the expansion part: you have at least one measurable tumor on imaging - You have either: HER2-positive bile duct cancer (biliary tract cancer), or a HER2-positive metastatic solid tumor other than breast or stomach cancer - You have provided a tumor tissue sample **You may NOT be eligible if...** - Your brain cancer (CNS metastases) is uncontrolled or you have spinal cord compression - You have heart failure or recent heart attack - You have lung inflammation (interstitial lung disease or pneumonitis) - You have HIV, active hepatitis B or C - You are on long-term steroid therapy or have an autoimmune disease - You have a history of a second primary cancer Talk to your doctor to see if this trial is right for you.